These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 18977669)

  • 1. The role of salvage treatment in advanced colorectal cancer.
    Capdevila J; Ramos FJ; Macarulla T; Elez E; Tabernero J
    Crit Rev Oncol Hematol; 2009 Jul; 71(1):53-61. PubMed ID: 18977669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Systemic treatment of metastatic colorectal cancer].
    Montemurro M; Achtari L; Röth A; Halkic N; Luthi F; Ozsahin M; Denys A; Bauer J; Demartines N; Leyvraz S
    Rev Med Suisse; 2008 May; 4(158):1254-7. PubMed ID: 18616207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Second-line chemotherapy for colorectal cancer].
    Komatsu Y; Sogabe S; Kawamoto Y; Iwanaga I; Uehata Y; Yuki S; Asaka M
    Gan To Kagaku Ryoho; 2009 May; 36(5):721-5. PubMed ID: 19461170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxaliplatin-based chemotherapy in the management of colorectal cancer.
    Capdevila J; Elez E; Peralta S; Macarulla T; Ramos FJ; Tabernero J
    Expert Rev Anticancer Ther; 2008 Aug; 8(8):1223-36. PubMed ID: 18699761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The management of colorectal liver metastases: Expanding the role of hepatic resection in the age of multimodal therapy.
    Chiappa A; Makuuchi M; Lygidakis NJ; Zbar AP; Chong G; Bertani E; Sitzler PJ; Biffi R; Pace U; Bianchi PP; Contino G; Misitano P; Orsi F; Travaini L; Trifirò G; Zampino MG; Fazio N; Goldhirsch A; Andreoni B
    Crit Rev Oncol Hematol; 2009 Oct; 72(1):65-75. PubMed ID: 19147371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
    Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
    Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progresses in the medical treatment of advanced colorectal cancer.
    Sultan-Amar V; Fabre-Guillevin E; Piedbois P
    Rocz Akad Med Bialymst; 2005; 50():97-100. PubMed ID: 16358946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of preoperative chemotherapy in patients with resectable colorectal liver metastases.
    Benoist S; Nordlinger B
    Ann Surg Oncol; 2009 Sep; 16(9):2385-90. PubMed ID: 19554377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line chemotherapy in metastatic colorectal cancer: new approaches and therapeutic algorithms. Always hit hard first?
    Loupakis F; Masi G; Vasile E; Falcone A
    Curr Opin Oncol; 2008 Jul; 20(4):459-65. PubMed ID: 18525344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Advance of salvage chemotherapy for colorectal cancer].
    Aiba K; Natori K
    Gan To Kagaku Ryoho; 2015 Apr; 42(4):394-7. PubMed ID: 25963685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-line management of metastatic colorectal cancer.
    Gallagher DJ; Kemeny N
    Clin Colorectal Cancer; 2008 Jan; 7(1):25-32. PubMed ID: 18279574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updated options for liver-limited metastatic colorectal cancer.
    Alberts SR
    Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S58-62. PubMed ID: 19064408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on chemotherapy for advanced colorectal cancer.
    Haller DG
    Oncology (Williston Park); 2001 Mar; 15(3 Suppl 5):11-5. PubMed ID: 11301834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-line therapy for esophageal cancer.
    Martin MG; Govindan R; Morgensztern D
    Expert Rev Anticancer Ther; 2007 Jun; 7(6):871-6. PubMed ID: 17555397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular markers of chemotherapeutic response and toxicity in colorectal cancer.
    Braun MS; Quirke P; Seymour MT
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):489-501. PubMed ID: 17428170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting.
    Gallagher DJ; Milowsky MI; Bajorin DF
    Cancer; 2008 Sep; 113(6):1284-93. PubMed ID: 18629841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermittent therapy in the palliative treatment of metastatic colorectal cancer.
    Wadhawan A; Stephens R; Adams R
    Expert Rev Anticancer Ther; 2009 Jan; 9(1):125-34. PubMed ID: 19105712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical benefit of new targeted agents in phase I trials in patients with advanced colorectal cancer.
    Arkenau HT; Brunetto AT; Barriuso J; Olmos D; Eaton D; de Bono J; Judson I; Kaye S
    Oncology; 2009; 76(3):151-6. PubMed ID: 19169046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer.
    Ramos FJ; Macarulla T; Capdevila J; Elez E; Tabernero J
    Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S52-7. PubMed ID: 19064407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic arterial infusion chemotherapy using fluorouracil followed by systemic therapy using oxaliplatin plus fluorouracil and leucovorin for patients with unresectable liver metastases from colorectal cancer.
    Seki H; Ozaki T; Shiina M
    Cardiovasc Intervent Radiol; 2009 Jul; 32(4):679-86. PubMed ID: 19296157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.